OPKO Health

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

OPKO Health reports robust Q4 performance and outlines growth strategies

OPKO Health's Q4 2022 earnings call highlighted positive performance, innovative strengths, challenges in market positioning, and opportunities for growth and profitability.
The company's focus on product development, operational efficiencies, and strategic clarity underscores a commitment to driving shareholder value and market leadership.
Analyst inquiries and management responses showcased transparency, strategic foresight, and a proactive approach to addressing market dynamics and regulatory challenges.

OPKO Health reports Q1 revenue growth, strategic partnerships with Merck

OPKO Health's Q1 2023 performance reflects revenue growth in Pharmaceuticals but challenges in Diagnostics segment revenue.
Strengths lie in strategic partnerships with Merck, diversified growth initiatives, and cost-saving measures.
Challenges include limited disclosure on NGENLA approval and revenue recognition complexities.
Opportunities exist in new revenue streams, specialty testing expansion, and strategic collaborations for future growth.
Overall, OPKO Health's performance showcases a mix of strengths, challenges, and opportunities for strategic growth and market leadership.

OPKO Health reports improved Q2 performance and growth opportunities

OPKO Health's Q2 2023 performance showed improvements in operating income and revenue despite challenges in the Diagnostics segment.
The company's strategic strengths lie in successful product approvals, collaborations with Merck, and revenue diversification efforts.
While facing challenges such as revenue fluctuations and profitability concerns, OPKO Health is poised for growth with promising opportunities ahead.
Overall, OPKO Health's financial outlook remains positive, with a focus on profitability and expansion through strategic initiatives and partnerships.

OPKO Health excels in Q3 with revenue growth and innovation

OPKO Health's Q3 2023 performance showcased revenue growth, strong product offerings, and strategic advancements in healthcare solutions.
The company's strengths include successful products, cost-cutting measures, and a focus on innovation through collaborations and contracts.
Challenges include the need for more detailed financial disclosures and transparent communication on operational metrics.
Amidst challenges, opportunities for growth through product expansion, partnerships, and operational optimization are key focus areas for OPKO Health.

OPKO Health excels in 2023 with strategic partnerships and growth

OPKO Health demonstrated strong performance in 2023 with key achievements and positive growth in sales and collaborations.
While facing challenges such as revenue decline in the Diagnostics segment, the company is actively addressing them through cost reduction efforts.
Strategic partnerships, financial refinancing, and clear guidance for 2024 position OPKO Health for continued success and growth.

OPKO Health sells assets, expands therapies globally for growth

OPKO Health is strategically streamlining operations and expanding globally.
Despite revenue declines, the company is focused on profitability and growth.
Strong progress in ModeX programs and collaborations for new therapies.
Emphasis on oncology testing and potential partnerships in oncology space.

OPKO Health reports robust Q2 performance and eyes growth opportunities

OPKO Health's Q2 2024 earnings call highlighted strong financial performance, strategic initiatives for growth, and a focus on operational efficiency and innovation.
The company faces challenges in managing expectations, addressing concerns, and navigating potential acquisitions, but opportunities in collaborations and market expansion are promising.
Overall, OPKO Health's disciplined approach to financial management, clinical development, and strategic partnerships positions it for continued success and value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

OPKO Health (OPK) delivered earnings and revenue surprises of 25.00% and 13.41%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

OPKO Health (OPK) Q4 Earnings and Revenues Surpass Estimates

Shares of OPKO Health (NASDAQ:OPK) rose in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 266.67% over the past year to $0.05, which beat the estimate of $0.04.

OPKO Health: Q4 Earnings Insights

OPKO Health's (OPK) fourth-quarter results are likely to reflect solid performance from Services and Products segment and RAYALDEE.

OPKO Health (OPK) to Report Q4 Earnings: What's in Store?

MIAMI, Feb. 03, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) plans to report operating and financial results for the three months ended December 31, 2020, as well as discuss financial guidance, after the close of the U.S. financial markets on Thursday, February 18, 2021. OPKO's senior management will provide a business update and discuss results in greater detail during a conference call and live audio webcast on February 18th beginning at 4:30 p.m. Eastern time.

OPKO Health to Report Fourth Quarter 2020 Financial Results on February 18, 2021

Clovis Oncology

Dynavax Technologies

Lannett Company

Cenntro Electric Group

Precigen

Senseonics Holdings

TherapeuticsMD

United Microelectronics

VBI Vaccines

The movement of retail traders against hedge funds has caused several stocks to spike. Many of the top movers have been stocks that have a high percentage of their floated shares short, causing what's known as a short squeeze.

10 Short Squeeze Candidates Under $10

DHT Holdings

Mustang Bio

RealNetworks

Rolls-Royce Holdings PLC

Penny stocks are cheap for a reason, as there are obvious flaws. However, with those flows comes opportunity.

7 Best Penny Stocks to Buy Early Into 2021

OPKO Health's (OPK) BioReference introduces an in-home, fully-integrated digital platform providing access to diagnostic services.

OPKO Health's (OPK) BioReference Extends Digital Health Access

OPKO Health, Inc. (OPK) CEO Phil Frost Presents at 39th Annual JPMorgan Virtual Healthcare Conference (Transcript)

ELMWOOD PARK, N.J., Jan. 13, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ:OPK), today introduced Scarlet Health™, an in-home, fully integrated digital platform providing access to on-demand diagnostic services. Scarlet has been designed similarly to...

OPKO Health's BioReference Laboratories Introduces Scarlet Health™, an In-Home Diagnostic Service to Expand Digital Health Access

Calls on Analysts and Stockholders Attending J.P. Morgan's Healthcare Conference to Determine Whether Management Disputes our Analysis and Stands by Original 4Q'20 Guidance Calls on Analysts and Stockholders Attending J.P. Morgan's Healthcare Conference to Determine Whether Management Disputes our Analysis and Stands by Original 4Q'20 Guidance

Sian Capital Urges OPKO Health to Address Apparently Misleading 4Q'20 Guidance

It's the perfect time for a wealthy CEO to ride off into the sunset.

3 Things to Expect from OPKO Health in 2021

MIAMI, Jan. 05, 2021 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in the 39th Annual J.P. Morgan Healthcare Conference being held virtually on January 11-14, 2021. Management will be hosting one-on-one meetings with investors and will be presenting on Wednesday, January 13th at 3:40 p.m. Eastern time.

OPKO Health to Present at the 39th Annual J.P. Morgan Healthcare Conference

OPKO Health's (OPK) BioReference commences mandatory, large-scale COVID-19 testing programs for fans for AFC Division Wild Card playoff game.

OPKO Health's (OPK) BioReference Starts Fan Testing Program

ELMWOOD PARK, N.J., Jan. 4, 2021 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced the results of COVID-19 molecular PCR tests for public schools throughout New York City's boroughs, with a positivity rate of 0.47 percent. BioReference...

OPKO Health's BioReference Laboratories Reports Results of the Largest COVID-19 Public School Testing Program Nationwide

Pfizer

NEW YORK & MIAMI--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and OPKO Health Inc. (NASDAQ: OPK) announced today that the US Food and Drug Administration (FDA) has accepted for filing the initial Biologics License Application (BLA) for somatrogon, a long-acting human growth hormone that is intended to be administered once-weekly for the treatment of pediatric patients with growth hormone deficiency (GHD). The target Prescription Drug User Fee Act (PDUFA) action date for decision by the FDA is in O

US FDA Accepts Regulatory Submission from Pfizer and OPKO for Review of Somatrogon to Treat Pediatric Patients with Growth Hormone Deficiency

OPKO Health has been experiencing an historic year in terms of business achievements, execution, and public recognition. The current Opko share price has been trading at extremely depressed levels recently for a variety of reasons.

OPKO Health: A $10 Stock On Sale Now For Only $4

Antares Pharma

Fluent Inc

These interesting low-cost stocks have the opportunity to grow.

3 Top Stocks Trading Under $5 a Share

MIAMI, Dec. 21, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced the appointment of Roger Medel, M.D. as an independent member of its Board of Directors, effective December 18, 2020. With this appointment, the OPKO Health Board has 11 Directors, including seven independent Directors.

OPKO Health Appoints Dr. Roger Medel to its Board of Directors

PAE Inc

Having college and professional athletes play sports during a pandemic can create logistics problems with social distancing and COVID-19 testing. Two small cap companies have won contracts to help leagues with testing.

2 Small Cap COVID-19 Test Companies With Sports Contract Wins

Rumors of a potential sale of the company's growth hormone royalty stream excited investors.

Why Opko Health Stock Jumped Today

OPKO Health, Inc. (OPK) Management Presents at Jefferies 2020 Virtual London Healthcare Conference (Transcript)

Kraft Heinz

Hanesbrands

Tupperware

Vertex Pharmaceuticals

Impinj

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider buying can be an encouraging signal for potential investors, particularly when there is uncertainty in the markets, as there was both before and after the elections.

Last Week's Notable Insider Buys: Kraft, IBM, Vertex And More

MIAMI, Nov. 11, 2020 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) today announced that management will be participating in three upcoming virtual investor conferences.

OPKO Health to Participate in Three Upcoming Investment Conferences

BioMarin Pharmaceutical

Patient investors could double their money in these two stocks that the market has temporarily cast aside.

2 Healthcare Stocks That Could Double Your Money

OPKO Health's (OPK) third-quarter results benefit from increase in RAYALDEE prescriptions.

News for OPKO Health Stock (OPK)